Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus COGNEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus COGNEX.
ARICEPT ODT vs COGNEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Reversible acetylcholinesterase inhibitor, increases acetylcholine concentration at cholinergic synapses.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
Initial dose 10 mg orally 4 times daily (40 mg/day); may increase by 10 mg/day every 6 weeks up to 160 mg/day (40 mg 4 times daily).
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life is approximately 7-10 hours; clinical context: allows twice-daily dosing in most patients.
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Primarily renal (approximately 40-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor